Cancer Research Technology
Log in Register
Menu

HCT 116-I6 Invasive Cell Line

Info

Catalogue Number 153208
Parental Line HCT 116
Host Human
Tissue Colon
Disease Keywords Colorectal cancer
Model Cancer Model
Relevance The HCT 116-I6 cell line is a sub-line of HCT 116 that demonstrates a 4- and 20-fold increase in migration and invasion rate respectively compared to the parental cell line. The increased migratory/invasion capacity seen in HCT116-I6 cells is a stable event and not due to increased proliferation rates.
Production Details HCT 116 cells were incubated in a Matrigel Invasion Chambers (MIC) for 72-96h. The cells that invaded through to the bottom chamber were collected and designated as ‘Invasive 1’ (I1). These cells were propagated and repeatedly passed through the MIC until highly invasive HCT116-I6 cells were selected.
Conditional No
Research Area Cancer, Cell Structure and Motility, Drug Discovery & Development
Growth/Phenotype Keywords Invasion, migration
Recommended Growing Conditions McCoy’s 5a Medium (GIBCO # 16600) + 10% FBS + 100 units/ml penicillin+ 100 μg/ml streptomycin
Cellosaurus ID CVCL_HG06

References

There are 4 reference entries for this reagent.

View All References

References: 4 entries

Dunne et al. 2016. Clin Cancer Res. 22(1):230-42. PMID: 26283684.

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Europe PMC ID: 26283684

Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.

AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.

Europe PMC ID: 24170546


Add a reference

References: 4 entries

Dunne et al. 2016. Clin Cancer Res. 22(1):230-42. PMID: 26283684.

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.

AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor